RxDoctor Payments Data

Samson Dankert, PA

Medical · Stockton, CANPI 1720703846

Payments from drug & device makers

$8,687in general payments, 2019–2025

Across 391 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • AbbVie$1K
  • E.r. Squibb & Sons, L.L.C.$625
  • Incyte Corporation$599
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$5006%
  • Food & beverage$7,77089%
  • Education$4175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,687 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$95,002
Medicare patients
341
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$41,416
ZoryveRoflumilast49$40,578
Fluocinonide86$2,959
Clobetasol Propionate36$2,434
Ketoconazole98$1,670
Doxycycline Hyclate65$1,344
Triamcinolone Acetonide130$912
Tretinoin11$566
ErythromycinErythromycin Base In Ethanol26$546
Prednisone14$48
Minoxidil12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$1,579$40,57849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →